Table 2.
Model parameters used in all countries
| Parameter | Base | Range | Distribution | Reference |
|---|---|---|---|---|
| Adherence to PQ7 regimen | 0.62 | 0.25–0.95 | Beta | 23–25 |
| Adherence to PQ14 regimen | 0.47 | 0.19–0.71 | Beta | Assumption that PQ7 adherence would be reduced by 25% for PQ14 |
| Adherence to PQ8W regimen | 0.31 | 0.13–0.48 | Beta | Assumption that PQ7 adherence would be reduced by 50% for PQ8W |
| Proportion of women who uptake referral to a higher facility for quantitative G6PD testing | 0.5 | 0.25–1.00 | Beta | Assumption |
| Relative increase in recurrences if PQ14 or TQ (instead of PQ7) was taken | 2.34 | 1.76–2.93 | Beta | ±25%5,22 |
| RDT sensitivity in males | 0.98 | 0.90–1.00 | Beta | 30% cutoff16 |
| RDT specificity in males | 0.97 | 0.90–1.00 | Beta | 30% cutoff16 |
| RDT sensitivity in females | 0.90 | 0.80–0.96 | Beta | 30% cutoff16 |
| RDT specificity in females | 0.68 | 0.50–0.97 | Beta | 30% cutoff16 |
| Quantitative test sensitivity | 0.95 | 0.89–0.98 | Beta | 70% cutoff20 |
| Quantitative test specificity | 0.82 | 0.68–0.91 | Beta | 70% cutoff20 |
| Proportion of G6PD patients who need a transfusion because of hemolysis after taking radical cure | 0.109 | 0.007–0.15 | Beta | Includes PQ7, PQ14, and tafenoquine40 |
| Proportion who need a transfusion because of hemolysis but do not receive it | 0.1 | 0.01–0.15 | Beta | 18 |
| Risk of death due to not receiving a transfusion | 0.1 | 0.01–0.5 | Beta | 18 |
| Proportion of recurrences that are severe | 0.02 | 0.013–0.027 | Beta | 41 |
| Proportion of recurrences that result in death | 0.0001 | 0–0.001 | Beta | 18 |
| Cost of TQ | $2 | $1.4-$3.0 | Gamma | Assumption |
| Length of illness: uncomplicated malaria | 3 days | 1–7 days | Beta | 18 |
| Length of illness: severe malaria | 7 days | 3–10 days | Beta | 18 |
| Length of illness: anemia due to malaria | 1 month | 0.5–2 months | Beta | 18 |
| Length of illness: anemia due to severe malaria or hemolysis | 3 months | 1–6 months | Beta | 18 |
| DALY weight for infectious disease: acute episode and moderate | 0.053 | 0.033–0.081 | Gamma | 29 |
| DALY weight for infectious disease: acute episode and severe | 0.210 | 0.139–0.298 | Gamma | 29 |
| DALY weight for moderate anemia | 0.058 | 0.038–0.086 | Gamma | 29 |
| DALY weight for severe anemia | 0.164 | 0.112–0.228 | Gamma | 29 |
DALY = disability-adjusted life-year; G6PD = glucose-6-phosphate dehydrogenase; PQ14 = 3.5 mg/kg total primaquine dose over 14 days; PQ7 = 7 mg/kg total primaquine dose over 7 days; PQ8W = 6 mg/kg total primaquine dose weekly for 8 weeks; TQ = tafenoquine; RDT = rapid diagnostic test.